Quantitative single-cell biomarkers of T-cells to optimize tumor immunotherapy

描述（由申请人提供）：免疫疗法注入抗体、疫苗和细胞是人类恶性肿瘤的有效治疗方法。有效的抗肿瘤作用是利用免疫系统的特异性和相关效应功能来识别和消除癌细胞。临床试验揭示了免疫疗法的优势，包括(i)明确的作用机制，（ii）明确的特异性和减少有害的脱靶效应，（iii）比传统方法的毒性更低。过继细胞疗法（ACT）基于T细胞的过继转移，通过基因修饰来增强嵌合抗原受体（CAR）的表达，在临床试验中显示出相当大的希望，可以治疗所有其他治疗方法都难以治愈的肿瘤。特别是，CAR+ T细胞对CD19特异性的使用在常规治疗难治性CD19+慢性淋巴细胞白血病（CLL）患者中显示出显著的抗肿瘤效果。这些试验注入异质的转基因T细胞群，这些细胞已经繁殖到临床足够的数量。虽然输注T细胞的治疗潜力取决于它们的持久性，但评估输注T细胞存活的免疫相关研究目前仅限于(i)描述接种的整个T细胞群体的免疫表型和功能，以及（ii）输注后恢复的T细胞的免疫表型分析。该资助申请旨在通过开发一个统一的平台来评估直接从免疫治疗受体获得的少量T细胞（和肿瘤细胞）（无需体外操作）的表型和功能，从而适应单细胞成像和检索，以了解临床级cd19特异性CAR+ T细胞的效力。我们的目标是使用我们开发的高通量单细胞纳米孔筛选（SNS）对输注前的CAR+ T细胞进行深入的定量功能表征（多重细胞因子分泌、表型、细胞毒性、调节性T细胞的作用、Treg），并将这些数据与输注后从患者身上恢复的T细胞进行比较。这些数据将用于(i)量化输注T细胞的功能和抗肿瘤作用的潜力，以及（ii）改善T细胞的产生，以便在下一代临床试验中获得更大的疗效。我们将在特异性目标1中验证我们的方法，我们将定义临床级cd19特异性CAR+ T细胞的综合功能和分子特征。在特异性目标2中，我们将实施我们的方法来量化过继转移细胞的体内持久性。这将验证SNS可以量化临床级T细胞的治疗潜力和形成下一代临床试验的假设。

DESCRIPTION (provided by applicant): Immunotherapy infusing antibodies, vaccines, and cells is an effective treatment approach for human malignancies. Potent anti-tumor effects are realized by harnessing the specificity and associated effector functions of the immune system to recognize and eliminate cancer cells. Clinical trials have revealed the advantages of immune-based therapies, including (i) defined mechanisms of action, (ii) defined specificity and reduced deleterious off-target effects, (iii) lower toxicities than conventional approaches. Adoptive cell therapy (ACT), based on the adoptive transfer of T cells genetically modified to enforce expression of a chimeric antigen receptor (CAR), has shown considerable promise in clinical trials treating tumors refractory to all other treatment methods. In particular, the use of CAR+ T cells rendered specific for CD19 demonstrated significant anti-tumor effects in patients with CD19+ chronic lymphocytic leukemia (CLL) refractory to conventional therapies. These trials infuse a heterogeneous population of genetically modified T cells which have been propagated to clinically-sufficient numbers. While the therapeutic potential of infused T cells depends on their persistence, immunocorrelative studies evaluating survival of infused T cells are currently limited to (i) describing the immunophenotypes and function of whole populations of the T-cell inoculum and (ii) immunophenotypic analyses on T cells recovered after infusion. This grant application seeks to adapt single- cell imaging and retrieval to inform on the potency of clinical-grade CD19-specific CAR+ T cells by developing a unified platform for assessing both phenotype and function on the few T cells (and tumor cells) directly obtained (without in vitro manipulation) from recipients of immunotherapy. Our objective is to use high throughput single-cell nanowell screening (SNS) that we have developed to undertake an in-depth quantitative functional characterization (multiplexed cytokine secretion, phenotype, cytotoxicity, effect of regulatory T cells, Treg) of pre-infusion CAR+ T cells and compare these data to T cells recovered from the patient, post-infusion. These data will be used to (i) quantify the functionalit of infused T cells and the potential for anti-tumor effects and (ii) improve the generation of T cells for greater efficacy in next-generation clinical trials. We will validate our approach in Specific Aim 1 where we will define the integrated functional and molecular profiles of clinical- grade CD19-specific CAR+ T cells. In Specific Aim 2 we will implement our methodology to quantify the in vivo persistence of adoptively transferred cells. This will test the hypothesis tha SNS can quantify the therapeutic potential of clinical-grade T cells and in the formation of next-generation clinical trials. PUBLIC HEALTH RELEVANCE: Genetically modified T cells are being infused in clinical trials to target leukemia and lymphomas. This grant application validates tools for investigating the ability of the infused T cells to target tumor cells and applies this approach to improve our understanding of their therapeutic benefit in clinical trials. This will enable investigators to develop approaches to generating even more effective T cells to target hematologic malignancies in next-generation clinical trials.